June 23, 2010
Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award. Colorado Companies to Watch is a dynamic business recognition program honoring second-stage companies headquartered in the state of Colorado that are developing valuable products and services, creating quality jobs, enriching communities, and ... Read more
June 21, 2010
Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company’s first product, VeriStrat®, which is used by physicians to help guide therapy for patients ... Read more
May 6, 2010
Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed ... Read more
April 19, 2010
Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone, M.D., Ph.D., Professor of Medicine and Cancer Biology, Vanderbilt University School of Medicine, on Friday, April 30th at the 2nd European Lung Cancer Conference ... Read more
February 5, 2010
Biodesix, Inc. announces that David Brunel, Chief Executive Officer, will present at the 2010 Personalized Medicine Partnerships Conference, Wednesday, February 24th, at 11:00 a.m. eastern time. The conference takes place February 22-24th at the Doubletree Hotel in Philadelphia, PA, and will include presentations by both diagnostic ... Read more
September 28, 2009
Funding to further the commercialization of VeriStrat®
Biodesix, Inc., a privately held molecular diagnostics company focused on proteomic-based diagnostics discovery and commercialization, announced today that it has completed the initial tranche of its $10 million Series B-1 financing round. The financing was led by existing shareholders and ... Read more
May 14, 2009
Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment
Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on ... Read more
May 5, 2009
Test will help oncologists guide treatment of patients with non-small cell lung cancer
Biodesix, Inc. today announces U.S. commercial availability of VeriStrat, a unique, blood-based, proteomic test for patients with advanced stage non-small cell lung cancer (NSCLC). VeriStrat identifies patients who are likely to have good or poor outcomes following treatment with ... Read more
December 5, 2008
Biodesix, Inc, announced today that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Dr. Beresford will help drive all business development activities including the establishment of relationships with pharmaceutical and biotechnology ... Read more
October 31, 2008
Biodesix, Inc. (the “Company”), is pleased to announce receipt of a CLIA registration number 06D1090464 which allows the Company to commercially market VeriStrat®, the serum molecular diagnostic test described in the Journal of the National Cancer Institute 2007 99(11):838-846. The Company is making VeriStrat® available to qualified physicians in locations where the ... Read more
